Experimental vaccine elicits robust response against both HIV and tuberculosis

May 22, 2012

Clinician researchers in China have developed a vaccine that acts simultaneously against HIV-1 and M. tuberculosis (Mtb). An estimated 14 million people worldwide are coinfected with the two pathogens. The research is published in the May 2012 issue of Clinical and Vaccine Immunology.

The vaccine is composed of from both pathogens. The team, led by Sidong Xiong of Fudan University, Shanghai, incorporated four Mtb epitopes (the part of an antigen that is recognized by the immune system) into a backbone composed of HIV-1 p24 protein, a protein that is known to produce against HIV-1. The logic of this construction: many epitopes are short , with poor unless they are introduced into a —which in this case was the p24 protein.

The vaccine induced cellular immune responses to both pathogens, in which immune system cells including macrophages search out and destroy pathogens; and humoral immune response against HIV-1, in which the immune system produces antibodies against the pathogen. The vaccine was tested in a mouse model. 

Tuberculosis is one of the leading causes of death worldwide; third, after hepatitis C and then HIV/AIDS among infectious diseases, according to the World Health Organization (WHO). An estimated 2 billion—28 percent of the world’s population—are infected with M. tuberculosis, but most of these infections are latent. However, HIV infection is the strongest risk factor for the progression of latent tuberculosis infection to active TB.  And TB is the direct cause of death in about one quarter of all deaths among people with HIV/AIDS, according to the WHO.

More information: X. Li, W. Xu, and S. Xiong, 2012. A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1. Clin. Vac. Immunol. 19:723-730.

Related Stories

Recommended for you

Gene transcription in virus-specific CD8 T cells differentiates chronic from resolving HCV

October 17, 2017
Massachusetts General Hospital (MGH) investigators have identified differences in gene transcription within key immune cells that may distinguish those individuals infected with the hepatitis C virus (HCV) who develop chronic ...

How cytoplasmic DNA triggers inflammation in human cells

October 17, 2017
A team led by LMU's Veit Hornung has elucidated the mechanism by which human cells induce inflammation upon detection of cytoplasmic DNA. Notably, the signal network involved differs from that used in the same context in ...

Early trials show potential for treating hay fever with grass protein fragments

October 13, 2017
Protein fragments taken from grass can help protect hay fever patients from allergic reactions to pollen grains.

Researchers find mechanism for precise targeting of the immune response

October 13, 2017
The immune system checks the health of cells by examining a kind of molecular passport. Sometimes, cells present the wrong passport, which can lead to autoimmune diseases, chronic inflammations or cancer. Scientists of the ...

Enzyme behind immune cell response revealed

October 12, 2017
Monash University researchers have revealed the role played by an enzyme that is pivotal to the process of clearing infection in the body. Moreover, they suggest that the enzyme may be a potential target for drug development ...

Calcium lets T cells use sugar to multiply and fight infection

October 11, 2017
A calcium signal controls whether immune cells can use the nutrients needed to fuel their multiplication into a cellular army designed to fight invading viruses.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.